Dianthus Therapeutics, Inc. /DE/
For the period ended Mar 31, 2026. Filed May 5, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 5, 2026
DNTH$88.81-1.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
(in thousands, except share and per share data)
| March 31,2026 | December 31,2025 | |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $627,667 | $51,087 |
| Short-term investments | 483,592 | 353,208 |
| Accounts receivable, net | 1,230 | 52 |
| Prepaid expenses and other current assets | 7,422 | 5,091 |
| Total current assets | 1,119,911 | 409,438 |
| Long-term investments | 113,868 | 110,135 |
| Property and equipment, net | 274 | 296 |
| Right-of-use operating lease assets | 1,293 | 1,337 |
| Other assets and restricted cash | 11,538 | 9,716 |
| Total assets | $1,246,884 | $530,922 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable | $5,274 | $9,725 |
| Accrued expenses | 31,125 | 19,452 |
| Current portion of deferred revenue | 1,485 | 1,188 |
| Current portion of operating lease liabilities | 399 | 367 |
| Total current liabilities | 38,283 | 30,732 |
| Deferred revenue | 6,322 | 5,770 |
| Long-term operating lease liabilities | 965 | 1,019 |
| Total liabilities | 45,570 | 37,521 |
| Commitments and contingencies (Note 14) | ||
| Stockholders’ equity: | ||
| Preferred stock; $0.001 par value per share; authorized shares – 10,000,000 at March 31, 2026 and December 31, 2025; issued and outstanding – none at March 31, 2026 and December 31, 2025 | — | — |
| Common stock; $0.001 par value per share; authorized shares – 150,000,000 at March 31, 2026 and December 31, 2025; issued and outstanding shares –54,582,749 and 43,223,090 at March 31, 2026 and December 31, 2025, respectively | 54 | 43 |
| Additional paid-in capital | 1,579,398 | 829,598 |
| Accumulated deficit | (377,563) | (336,729) |
| Accumulated other comprehensive (loss)/income | (575) | 489 |
| Total stockholders’ equity | 1,201,314 | 493,401 |
| Total liabilities and stockholders’ equity | $1,246,884 | $530,922 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.